Tuesday, 29th of March 2022
12:00 - 12:55pm CEST/ 6:00 - 6:55pm SGT/CST
The World Thrombosis Day (WTD) campaign seeks to increase global awareness of thrombosis, including its causes, risk factors, signs/symptoms and evidence-based prevention and treatment. This closely aligns with Roche’s dedication and commitment to innovating diagnostics by developing healthcare solutions to improve patient’s care.1
In partnership with WTD and led by expert researchers, we look at the predictive role of biomarkers in cancer-associated thrombosis. Venous thromboembolism (VTE) is a common complication in patients with cancer. Latest research indicates that cancer patients are at four times higher risk than the general population of developing serious blood clots. This increased risk of thrombosis is driven and modified by risk factors including cancer-specific factors such as type, histology, and stage of the malignancy, cancer treatment and certain biomarkers. 2
The prevalence and incidence of cancer-associated thrombosis (CAT) is rising 3,4, which leads to an increasing need for VTE risk assessment models, to be able to identify patients who would benefit from anticoagulation. Coagulation biomarkers are not only very useful to determine the thrombotic risk, but find its use as well in monitoring cancer progression and overall prognosis. 5
Expand your knowledge and engage in live discussions with Prof. Anna Falanga and Cinzia Giaccherini on cancer-associated thrombosis (CAT) in support of the World Thrombosis Day campaign.
